Using newly constructed antigen binding fragment (Fab) phage display libraries, Pitt researchers have identified and characterized fully human Fabs to the CD22-D7 domain, targeting the membrane-proximal immunoglobulin domain D7. These binders show nanomolar-level binding affinity to the recombinant D7 protein and specific binding to CD22-expressing lymphoma cell lines. Their sequences and binding epitopes are distinct from a highly clinically-successful monoclonal antibody, m971, previously discovered by the same lab. These binders have significant potential to be incorporated into CAR-T cells for leukemia and lymphoma treatment; in addition, these antibodies can be further developed into other therapeutic modalities, such as IgG1s, immunotoxins, and antibody drug conjugates.